image
Healthcare - Medical - Devices - NASDAQ - US
$ 22.88
-1.68 %
$ 1.77 B
Market Cap
-254.22
P/E
1. INTRINSIC VALUE

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices.[ Read More ]

The intrinsic value of one IART stock under the base case scenario is HIDDEN Compared to the current market price of 22.9 USD, Integra LifeSciences Holdings Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IART

image
FINANCIALS
1.54 B REVENUE
-1.03%
112 M OPERATING INCOME
-53.32%
67.7 M NET INCOME
-62.48%
140 M OPERATING CASH FLOW
-47.08%
-94.2 M INVESTING CASH FLOW
-60.77%
-230 M FINANCING CASH FLOW
8.74%
381 M REVENUE
-8.93%
-8.15 M OPERATING INCOME
-23.12%
-10.7 M NET INCOME
13.76%
22.5 M OPERATING CASH FLOW
-44.35%
-10.4 M INVESTING CASH FLOW
96.77%
-19.9 M FINANCING CASH FLOW
78.76%
Balance Sheet Decomposition Integra LifeSciences Holdings Corporation
image
Current Assets 1.06 B
Cash & Short-Term Investments 309 M
Receivables 259 M
Other Current Assets 490 M
Non-Current Assets 2.72 B
Long-Term Investments 32.2 M
PP&E 496 M
Other Non-Current Assets 2.2 B
Current Liabilities 307 M
Accounts Payable 92.3 M
Short-Term Debt 29.8 M
Other Current Liabilities 185 M
Non-Current Liabilities 1.89 B
Long-Term Debt 1.65 B
Other Non-Current Liabilities 235 M
EFFICIENCY
Earnings Waterfall Integra LifeSciences Holdings Corporation
image
Revenue 1.54 B
Cost Of Revenue 653 M
Gross Profit 888 M
Operating Expenses 836 M
Operating Income 112 M
Other Expenses 43.8 M
Net Income 67.7 M
RATIOS
57.63% GROSS MARGIN
57.63%
7.23% OPERATING MARGIN
7.23%
4.39% NET MARGIN
4.39%
4.27% ROE
4.27%
1.79% ROA
1.79%
3.02% ROIC
3.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Integra LifeSciences Holdings Corporation
image
Net Income 67.7 M
Depreciation & Amortization 124 M
Capital Expenditures -66.9 M
Stock-Based Compensation 20.1 M
Change in Working Capital -81.6 M
Others 15.9 M
Free Cash Flow 73.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Integra LifeSciences Holdings Corporation
image
Wall Street analysts predict an average 1-year price target for IART of $26.6 , with forecasts ranging from a low of $20 to a high of $40 .
IART Lowest Price Target Wall Street Target
20 USD -12.59%
IART Average Price Target Wall Street Target
26.6 USD 16.37%
IART Highest Price Target Wall Street Target
40 USD 74.83%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Integra LifeSciences Holdings Corporation
image
Sold
0-3 MONTHS
25.7 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
305 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
2.5 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 19, 2024
Sell 25.7 K USD
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
- 1191
21.5792 USD
5 months ago
May 23, 2024
Bought 1.5 M USD
ESSIG STUART
Exec. Chairman of the Board
+ 52641
28.4945 USD
5 months ago
May 21, 2024
Bought 996 K USD
HILL BARBARA B
Director
+ 36350
27.3952 USD
8 months ago
Mar 06, 2024
Sell 305 K USD
DAVIS ROBERT T. JR.
EVP & President, TT
- 8348
36.5946 USD
1 year ago
Aug 09, 2023
Sell 52.3 K USD
Mosebrook Jeffrey
SVP, Fin & PAO
- 1177
44.46 USD
1 year ago
Jun 01, 2023
Bought 100 K USD
Schwartz Eric
EVP, Chief Legal Officer & Sec
+ 2640
37.8921 USD
1 year ago
Jun 01, 2023
Bought 300 K USD
De Witte Jan
President & CEO
+ 7792
38.4992 USD
1 year ago
Mar 07, 2023
Sell 100 K USD
McBreen Michael J.
EVP & President, CSS
- 1843
54.2943 USD
1 year ago
Mar 01, 2023
Sell 86.5 K USD
DAVIS ROBERT T. JR.
EVP & President, TT
- 1566
55.2127 USD
1 year ago
Feb 27, 2023
Sell 215 K USD
Evoli Lisa
EVP & CHRO
- 3767
57.0031 USD
1 year ago
Dec 08, 2022
Sell 15.7 K USD
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
- 279
56.2162 USD
2 years ago
Aug 10, 2022
Sell 65 K USD
Evoli Lisa
Executive Vice President &CHRO
- 1165
55.8108 USD
2 years ago
Aug 05, 2022
Sell 446 K USD
Murphy Raymond G.
director:
- 8000
55.7833 USD
2 years ago
Aug 02, 2022
Sell 24.8 K USD
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
- 437
56.775 USD
2 years ago
Jun 15, 2022
Sell 50.3 K USD
Evoli Lisa
Executive Vice President &CHRO
- 900
55.93 USD
2 years ago
May 24, 2022
Sell 15 K USD
Evoli Lisa
Executive Vice President &CHRO
- 250
59.8501 USD
2 years ago
Apr 04, 2022
Sell 414 K USD
Coleman Glenn
Executive Vice President & COO
- 6268
66.04 USD
2 years ago
Dec 16, 2021
Sell 4.82 M USD
Tru St Partnership, L.P.
10 percent owner
- 75000
64.28 USD
2 years ago
Feb 09, 2022
Sell 4.94 M USD
Tru St Partnership, L.P.
10 percent owner
- 75000
65.82 USD
2 years ago
Mar 23, 2022
Sell 9.7 M USD
Tru St Partnership, L.P.
10 percent owner
- 150000
64.67 USD
2 years ago
Feb 28, 2022
Sell 84.1 K USD
Evoli Lisa
Executive Vice President &CHRO
- 1254
67.03 USD
3 years ago
Nov 18, 2021
Sell 5.14 M USD
Tru St Partnership, L.P.
10 percent owner
- 75000
68.59 USD
3 years ago
Nov 10, 2021
Sell 49.6 K USD
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
- 700
70.88 USD
3 years ago
Nov 05, 2021
Sell 247 K USD
McBreen Michael J.
EVP & President, CSS
- 3450
71.5918 USD
3 years ago
Nov 02, 2021
Sell 316 K USD
Coleman Glenn
Executive Vice President & COO
- 4275
74 USD
3 years ago
Oct 20, 2021
Sell 14 M USD
Tru St Partnership, L.P.
10 percent owner
- 200000
69.81 USD
3 years ago
Sep 02, 2021
Sell 5.46 M USD
Arduini Peter J
President & CEO
- 71829
75.9674 USD
3 years ago
Sep 03, 2021
Sell 3.53 M USD
Arduini Peter J
President & CEO
- 46605
75.7528 USD
3 years ago
Aug 06, 2021
Sell 285 K USD
McBreen Michael J.
EVP & President, CSS
- 4000
71.2215 USD
3 years ago
Jun 03, 2021
Sell 84.2 K USD
Murphy Raymond G.
Director
- 1253
67.215 USD
3 years ago
May 10, 2021
Sell 206 K USD
Evoli Lisa
Executive Vice President &CHRO
- 2745
75 USD
3 years ago
Apr 16, 2021
Sell 1.83 M USD
Coleman Glenn
Executive Vice President & COO
- 25658
71.5 USD
3 years ago
Apr 14, 2021
Sell 282 K USD
Coleman Glenn
Executive Vice President & COO
- 4002
70.5 USD
3 years ago
Apr 14, 2021
Sell 125 K USD
Evoli Lisa
Executive Vice President &CHRO
- 1785
70 USD
3 years ago
Apr 09, 2021
Sell 875 K USD
Coleman Glenn
Executive Vice President & COO
- 12500
70 USD
3 years ago
Mar 29, 2021
Sell 856 K USD
Coleman Glenn
Executive Vice President & COO
- 12500
68.5 USD
3 years ago
Feb 18, 2021
Sell 5 M USD
Tru St Partnership, L.P.
10 percent owner
- 70275
71.15 USD
3 years ago
Mar 18, 2021
Sell 49.7 M USD
Tru St Partnership, L.P.
10 percent owner
- 730000
68.14 USD
3 years ago
Mar 18, 2021
Sell 14.6 M USD
ESSIG STUART
Director
- 214553
68.14 USD
3 years ago
Mar 02, 2021
Sell 72.7 K USD
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
- 1058
68.6994 USD
3 years ago
Mar 02, 2021
Sell 152 K USD
McBreen Michael J.
EVP & President, CSS
- 2205
69 USD
3 years ago
Mar 02, 2021
Sell 291 K USD
Schwartz Eric
EVP, Chief Legal Officer & Sec
- 4212
69.0956 USD
3 years ago
Feb 25, 2021
Sell 159 K USD
Schwartz Eric
EVP, Chief Legal Officer & Sec
- 2288
69.52 USD
3 years ago
Feb 25, 2021
Sell 1.73 M USD
DAVIS ROBERT T. JR.
EVP & President, TT
- 24941
69.4825 USD
3 years ago
Feb 01, 2021
Sell 1.51 M USD
Arduini Peter J
President & CEO
- 22786
66.1565 USD
3 years ago
Dec 17, 2020
Sell 12.2 M USD
Tru St Partnership, L.P.
10 percent owner
- 200000
60.77 USD
3 years ago
Dec 18, 2020
Sell 2.79 M USD
Arduini Peter J
President & CEO
- 45000
61.9729 USD
4 years ago
Nov 13, 2020
Sell 146 K USD
Coleman Glenn
Executive Vice President & COO
- 2600
56.0255 USD
4 years ago
Nov 12, 2020
Sell 151 K USD
Murphy Raymond G.
Director
- 2839
53.16 USD
4 years ago
Nov 09, 2020
Sell 267 K USD
Coleman Glenn
Executive Vice President & COO
- 4907
54.3445 USD
4 years ago
Nov 09, 2020
Sell 5.12 K USD
Coleman Glenn
Executive Vice President & COO
- 93
55.04 USD
4 years ago
Nov 09, 2020
Sell 247 K USD
Coleman Glenn
Executive Vice President & COO
- 4400
56.0447 USD
4 years ago
Nov 09, 2020
Sell 139 K USD
McBreen Michael J.
EVP & President, CSS
- 2500
55.5484 USD
4 years ago
Nov 09, 2020
Sell 226 K USD
Evoli Lisa
Executive Vice President &CHRO
- 4424
51 USD
4 years ago
Nov 09, 2020
Sell 141 K USD
Evoli Lisa
Executive Vice President &CHRO
- 2552
55.182 USD
4 years ago
Sep 17, 2020
Sell 9.39 M USD
Tru St Partnership, L.P.
10 percent owner
- 200000
46.97 USD
4 years ago
Aug 13, 2020
Sell 41.7 K USD
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
- 807
51.6837 USD
4 years ago
Aug 11, 2020
Sell 261 K USD
Coleman Glenn
Executive Vice President & COO
- 5000
52.2685 USD
4 years ago
Jun 18, 2020
Sell 29.1 M USD
CARUSO RICHARD E
10 percent owner
- 600000
48.47 USD
4 years ago
Jun 05, 2020
Sell 191 K USD
Evoli Lisa
Chief Human Resources Officer
- 3475
55 USD
4 years ago
May 26, 2020
Sell 2.44 M USD
ESSIG STUART
Director
- 46807
52.0803 USD
4 years ago
May 27, 2020
Sell 4.66 M USD
ESSIG STUART
Director
- 89479
52.131 USD
4 years ago
May 28, 2020
Sell 609 K USD
ESSIG STUART
Director
- 11626
52.4017 USD
4 years ago
May 12, 2020
Sell 109 K USD
ESSIG STUART
Director
- 2087
52.0743 USD
4 years ago
May 11, 2020
Sell 289 K USD
REUVERS DANIEL L.
CVP,PRES - CODMAN SPC SURGICAL
- 5486
52.59 USD
4 years ago
Feb 26, 2020
Sell 1.8 M USD
Arduini Peter J
President & CEO
- 32316
55.6793 USD
4 years ago
Feb 24, 2020
Sell 2.19 M USD
Arduini Peter J
President & CEO
- 37704
58.2146 USD
4 years ago
Feb 21, 2020
Sell 1.21 M USD
Arduini Peter J
President & CEO
- 20344
59.562 USD
4 years ago
Feb 25, 2020
Sell 202 K USD
Arduini Peter J
President & CEO
- 3540
57.1159 USD
4 years ago
Dec 19, 2019
Sell 29.2 M USD
CARUSO RICHARD E
10 percent owner
- 491205
59.42 USD
4 years ago
Dec 05, 2019
Sell 247 K USD
Schwartz Eric
Corp VP, Gen Counsel & Sec
- 4007
61.6222 USD
5 years ago
Sep 19, 2019
Sell 31.7 M USD
CARUSO RICHARD E
10 percent owner
- 520000
60.9695 USD
7. News
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs. zacks.com - 3 days ago
Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue globenewswire.com - 3 days ago
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter. zacks.com - 1 week ago
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Transcript Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witte - President and CEO Lea Knight - CFO Conference Call Participants Steven Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Kristen Stewart - C.L. King Robbie Marcus - JPMorgan Matt Taylor - Jefferies Richard Newitter - Truist Securities Craig Bijou - Bank of America Securities Joanne Wuensch - Citi Chris Ward Good morning and thank you for joining the Integra LifeSciences Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 week ago
Integra (IART) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago. zacks.com - 1 week ago
Integra LifeSciences Reports Third Quarter 2024 Financial Results PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. globenewswire.com - 1 week ago
Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development globenewswire.com - 1 week ago
Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024 PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. globenewswire.com - 1 month ago
Here's Why You Should Hold IART Stock in Your Portfolio Now Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock. zacks.com - 1 month ago
Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the Morgan Stanley Healthcare conference on September 6, 2024 at 10:45am ET. globenewswire.com - 2 months ago
Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm ET. globenewswire.com - 2 months ago
8. Profile Summary

Integra LifeSciences Holdings Corporation IART

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.77 B
Dividend Yield 0.00%
Description Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Contact 1100 Campus Road, Princeton, NJ, 08540 https://www.integralife.com
IPO Date Aug. 16, 1995
Employees 3946
Officers Ms. Chantal Veillon-Berteloot Executive Vice President & Chief Human Resources Officer Mr. Jeffrey A. Mosebrook Senior Vice President of Finance & Principal Accounting Officer Mr. Robert T. Davis Jr. Executive Vice President & President of Tissue Technologies Dr. Stuart M. Essig Ph.D. Executive Chairman Mr. Stephen Leonard Corporate Vice President of Global Operations & Supply Chain Laurene Isip Vice President of Global Corporate Communications & Public Relations Mr. Jan De Witte President, Chief Executive Officer & Director Ms. Lea Daniels Knight Executive Vice President & Chief Financial Officer Mr. Michael J. McBreen Executive Vice President & President of Codman Specialty Surgical Ms. Ruth L. Fleming Vice President of Global Marketing